Monopar Therapeutics Annual Report: A Summary

I’ve put together this guide to help you understand how Monopar Therapeutics performed this year. Instead of digging through dense legal filings, we’ll break down the key points so you can decide if this company fits your investment goals.

1. What does this company do?

Monopar is a clinical-stage biotech company. Think of them as a high-stakes research lab. They are developing new drugs—specifically MNPR-101 for advanced cancers and ALXN1840 for Wilson disease—but they aren't selling products yet. They have no sales revenue. Their business model relies on funding research until they prove a drug works, win FDA approval, and potentially partner with or sell to a larger pharmaceutical firm.

2. Financial performance: The "Cash Burn"

Because they have no products for sale, Monopar generates no revenue. For the year ending December 31, 2025, the company lost about $8.2 million, mostly on research and development. They spend much more than they bring in. To keep the lights on, they sell shares of stock to investors.

As of March 2026, the company has roughly 6.7 million shares outstanding. They frequently issue new shares to raise cash. For you, this means more shares are issued, reducing your ownership percentage (dilution). This is a constant necessity given their negative cash flow.

3. Major wins and infrastructure

The company is building its own infrastructure. In 2025, they moved their headquarters and secured a 10,000-square-foot laboratory in North Chicago. This allows them to do more hands-on research, reducing their reliance on expensive outside contractors. They also signed a licensing agreement with TacticPharma for ALXN1840. This deal offers potential future payments and royalties if the drug reaches the market.

4. Financial health

Monopar manages its cash carefully. They hold about $6.5 million in cash and short-term U.S. Treasury securities. With a quarterly burn rate of about $2.0 million, they have roughly 9 to 12 months of funding left. They are constantly seeking new capital to ensure their research continues.

5. Key risks

• The "All-or-Nothing" Nature of Biotech: If their drug trials fail, the stock price often drops significantly. The company’s value depends almost entirely on the success of its pipeline.
• Dilution: They will likely sell more shares to fund future trials. This reduces your ownership percentage over time and can lower the share price.
• Regulatory Hurdles: They depend on the FDA. Any delays or requests for more data can set them back years and drain their remaining cash.
• Cybersecurity: As a small firm, they are vulnerable to data breaches. Losing their proprietary research data would be catastrophic.

6. Future outlook

Monopar is in the "build" phase. Their future depends on successful clinical trials and securing enough funding to avoid running out of cash. They are currently focused on advancing MNPR-101 through early trials and moving ALXN1840 toward regulatory review. Expect continued volatility as the company approaches key data updates.

Final Thought for Investors: Investing in a company like Monopar is a bet on their scientific pipeline. Because they have no revenue and a limited cash runway, your primary focus should be on their ability to hit clinical milestones and their ongoing need to raise capital. If you are risk-averse, the constant need for funding and the binary nature of drug trials are the most important factors to keep in mind.